What I am working with: dulaglutide · 25 °C.
This is a procedural question rather than a theoretical one, and I would like the procedure rather than the theory.
What I have done so far is read the label documentation where it exists and the two pharmacopoeial monographs that are publicly available, which cover the licensed presentation and say nothing about a research one.
What would you do, and what would you check afterwards?
Whatever the refrigerated figure is, divide it by about 4. 25 °C is 20 kelvin above the 5 °C middle of a 2–8 °C refrigerator. The ten-degree rule of thumb — degradation rate roughly doubling per 10 K — makes that about 4 times the refrigerated rate, which is an order-of-magnitude statement and not a shelf life. So a preparation with a twenty-eight day refrigerated figure has roughly 7 days at 25 °C on the same assumption — an order-of-magnitude answer, not a shelf life, and it says nothing about sterility, which has its own clock. "Within specification" also needs a specification: purity, content, or both, and at what limit. Without that the question has no numerical answer at all.
Start with the sequence, because which pathways are available depends on which residues are present.
A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.
Freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.
Nothing here is medical advice, and research-use compounds are not approved for human use.
At dilute concentrations, suspect adsorption before you suspect chemistry.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsMechanically, aggregation is a physical process and is the one most often caused by handling rather than by time.
Adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.
Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.
Apparent loss in a dilute preparation is usually adsorption rather than degradation and is worth ruling out first.
Sequence decides which pathways are even available. Check the residues.
The short version: water enables most of it, oxygen enables oxidation, surfaces enable adsorption, and agitation enables aggregation.
Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.
Specifically, deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.
Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.
Swirl, never shake. Aggregation is a handling problem more than a time problem.
Concretely, asparagine and glutamine are the deamidation risk, and methionine is the oxidation risk.
Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.
Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.
Cold, dry, dark, still. Those four words cover most of the mitigation.
Answering this needs the physical state, since a dry powder is protected from most of these and a solution is protected from none.
Light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.
The caveat is that none of these pathways can be seen by looking at a vial, and a clear solution can be substantially degraded.
A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.